1.The analysis of mammographic and ultrasonographic diagnosis value for nonspecific mastitis
Journal of Practical Radiology 2017;33(7):1013-1015,1023
Objective To analyze retrospectively the result of nonspecific mastitis diagnosed by mammography and color Doppler's ultrasonic, and to improve the diagnosis accuracy of nonspecific mastitis as well as the ability to identify with breast cancer.Methods 31 cases of nonspecific mastitiswere examined by mammography and color Doppler's ultrasonic.All cases were punctured by biopsy or surgery, and confirmed by pathology.Results The coincidence rates between mammography and color Doppler's ultrasonic with pathology were 64.5% and 67.7% respectively.The coincidence rate between the combined mammography and color Doppler's ultrasonic with pathology were 87.1%.There was no statistically significant difference between the two separate inspection methods (P>0.05).Conclusion Mammography and color Doppler's ultrasonic have their own advantages in the diagnosis of nonspecific mastitis, and are easy to be confused with breast cancer.Combining mammography with ultrasonography can improve the accuracy of unspecific mastitis diagnosis and the ability to identify breast cancer.
2.Therapeutic effects of percutaneous alternating cryogenic-heating therapy for nonresectable hepa-tocellular carcinoma
China Oncology 2001;0(05):-
Purpose:To study the therapeutic effects of beta-ultrasound guided percutaneous alternating cryogenic- heating therapy(ACHT) through liver puncture combined with other regional therapy for advanced hepatocellular carcinoma. Methods:68 patients with advanced hepatocelluar carcinomas were divided into 4 groups.Group A,17 patients are treated with ACHT plus transcatheter hepatic arterial chemoembolization(TACE).Group B,16 patients were treated with ACHT plus intravenous chemotherapy;GroupC,19 patients were treated with TACE only;GroupD,16 patients were treated with in- travenous chemotherapy only.Results:In ACHT+TACE group,the rate of complete response(CR) plus partial response (PR) was 88.2%,the 0.5-,1-year survival rates were 94.1%,94.1%,the rate of AFP decreased was 84.6%.In ACHT+ ICT group,the rate of complete response(CR) plus partial response(PR) was 87.5%,the 0.5-,1-year survival rates were 87.5%,68.8%,the rate of AFP decreased was 78.6%.In the TACE group,the rate of complete response(CR) plus par- tial response(PR) was 57.6%,the 0.5-,1-year survival rates were78.9%,42.1%,the rate of AFP decreased was 69.2%. In ICT group,the rate of complete response(CR) plus partial response(PR) was 25.0%,the 0.5-,1-year survival rates were 50.0%,18.8%,the rate of AFP decreased was 41.7%.For CR+PR,ACHT+TACE group and ACHT+ICT group were significantly higher than TACE group and ICT group,but significant changes between ACHT+TACE group and ACHT +ICT group were not found.For survival rates,ACHT+TACE group was significantly higher than the other 3 groups, ACHT+ICT group was significantly higher than ICT group.There were no serious side effects after chemotherapy except that 5 patients' leucocytes decreased to degree Ⅲ.The postoperative complications after ACHT included bleeding,hemoglo- binuria and reactive thoracic,which disappeared after short term treated.Conclusions:Alternating cryogenic-heating therapy (ACHT) through liver puncture combined with other regional therapy is effective in treating advanced hepatocellular carci- noma and its side effects and postoperative complications are mild.
4.Anti-EGFR monoclonal antibodies in locally advanced head and neck squamous cell carcinoma: a Meta-analysis.
Qi SONG ; Xiaoming LI ; Bin LI ; Bin DI ; Shufen XIAO
Journal of Clinical Otorhinolaryngology Head and Neck Surgery 2015;29(9):815-821
OBJECTIVE:
To perform a Meta-analysis of all randomized controlled trials that compared the efficacy and adverse events profile of Mabs for LA HNSCC.
METHOD:
Several databases were searched, including CBM, PUBMED, EMBASE, and CENTRAL. Primary outcomes included overall response rate (ORR), overall survival (OS), progression-free survival (PFS). Secondary outcomes included serious adverse events, such as grade 3-4 skin reaction, dysphagia, mucositis, and nausea/vomiting. The results were expressed as relative ratio (RR) or hazard rate (HR) with their corresponding 95% CI.
RESULT:
The final analysis included 10 trials. The primary analyses indicated that Mabs did not improve ORR and PFS, except OS for locoregionally advanced (LA) HNSCC [ORR 1.21, 95% CI (0.97 - 1.49); PFS 0.87, 95% CI (0.75 - 1.01); OS 0.82, 95% CI (0.71 - 0.95)]. Analysis of adverse effects demonstrated that grade 3 - 4 skin reaction ERR 1.87, 95% CI (1.11 - 3.16)] was statistically significantly associated with Mabs except dysphagia ERR 0. 95, 95% CI (0.75 - 1.19)], Mucositis ERR 1.03, 95% CI (0.67 - 1.57)], and nausea/vomiting ERR 1.15, 95% CI (0.71 - 1.86)].
CONCLUSION
Anti-EGFR Mabs may be satisfactory for improving OS of LA HNSCC. During the Mabs therapy, skin reaction should be much more monitored.
Antibodies, Monoclonal
;
therapeutic use
;
Antineoplastic Agents
;
therapeutic use
;
Carcinoma, Squamous Cell
;
drug therapy
;
Disease-Free Survival
;
ErbB Receptors
;
immunology
;
Head and Neck Neoplasms
;
drug therapy
;
Humans
;
Randomized Controlled Trials as Topic
;
Squamous Cell Carcinoma of Head and Neck
5. Vacuum-compression therapy for ischemic disease of the extremities: Experience with 40 patients
Academic Journal of Xi'an Jiaotong University 2009;21(3):206-208
Objective: To study the clinical effects of vacuum-compression therapy for ischemic disease of the extremities. Methods: A total of 40 cases of peripheral arterial disorders, including 23 thromboangiitis obliterans (31 limbs) and 17 arteriosclerosis obliterans (23 limbs), were treated by a self-made vacuum-compression therapeutic apparatus. Results: The effective rate in thromboangiitis obliterans and arteriosclerosis obliterans groups was 96.77% and 92.23%, respectively. The cuffs on the apparatus were improved to eliminate discomfort in the patients during treatment. "Rebound symptom" was observed during treatment, which had not been reported previously. Conclusion: Vacuum-compression therapy has a good prospect for treating ischemia of the extremities.
6. Vacuum-compression therapy for ischemic disease of the extremities: Experience with 40 patients
Academic Journal of Xi'an Jiaotong University 2009;21(3):206-208
Objective: To study the clinical effects of vacuum-compression therapy for ischemic disease of the extremities. Methods: A total of 40 cases of peripheral arterial disorders, including 23 thromboangiitis obliterans (31 limbs) and 17 arteriosclerosis obliterans (23 limbs), were treated by a self-made vacuum-compression therapeutic apparatus. Results: The effective rate in thromboangiitis obliterans and arteriosclerosis obliterans groups was 96.77% and 92.23%, respectively. The cuffs on the apparatus were improved to eliminate discomfort in the patients during treatment. "Rebound symptom" was observed during treatment, which had not been reported previously. Conclusion: Vacuum-compression therapy has a good prospect for treating ischemia of the extremities.
7.Cetuximab in head and neck squamous cell carcinoma: a systematic review and Meta-analysis.
Qi SONG ; Xiaoming LI ; Bin LI
Journal of Clinical Otorhinolaryngology Head and Neck Surgery 2015;29(1):67-75
OBJECTIVE:
To-evaluate the role and clinical value of cetuximab in the treatment of head and neck squamous cell carcinoma (HNSCC), and figure out its effectiveness and application, so as to develop evidence-based recommendations for treatment.
METHOD:
We comprehensively searched the CBM, Pubmed, EMBASE, and the Cochrane databases to identify published studies on the effect of cetuximab in HNSCC patients. Primary outcomes included overall survival (OS), progression-free survival(PFS) and overall response rate(ORR). Secondary outcomes included serious adverse events, such as neutropenia, anemia, thrombocytopenia, skin reactions, hypokalemia, vomiting, asthenia, hypomagnesemia, dyspnea and sepsis. Results were dispalyed as risk ratio (RR), odds ratio (OR), mean difference (MD) and 95% CI.
RESULT:
A Meta-analysis was conducted on 4 randomized controlled trials, including 2 trials comprising 1,319 patients with locally advanced HNSCC and 2 trails comprising 559 patients with recurrent or metastatic HNSCC. For locally advanced HNSCC, the 2 year PFS and OS showed no significant differences in patients received cetuximab or not (PFS fixed effect: RR=1.02, 95%CI 0.92-1.12, P>0.05; OS fixed effect: RR=1.06, 95%CI 1.00-1.13, P>0.05, respectively). Grade 3-4 dysphagia was also similar in patients treated with cetuximab or no cetuximab (dysphagia: fixed effect: RR = 0.92; 95% CI 0.84-1.02, P>0. 05). Only grade 3-4 mucositis and skin reaction showed statistical significance between patients treated with cetuximab and patients with no cetuximab (mucositis: fixed effect: RR=1.21; 95%CI 1.07-1. 36, P<0. 05; skin reaction: fixed effect: RR=1.99; 95%CI 1.39-2.85, P<0.05, respectively). For recurrent or metastatic HNSCC, the OS overall mean difference was 2.41 (95% CI 0.96-3.86, P<0.05), the PFS overall mean difference was 2. 06 (95% CI 1.34 - 2.77, P<0.05), and the ORR overall Odds ratio was 2.38 (95% CI 1.60-3.54,P<0.05), suggesting significant effect of cetuximab in improving the prognosis of R/M HNSCC. Owing to small number of trials it was not possible to assess the presence of publication bias. Of note, the 1 year survival overall Odds ratio was 1.39 (95% CI 0.98-1.97, P>0.05). The grade 3 or 4 adverse effects were described in 83. 4% of patients in cetuximab group and 75. 5% of patients in no cetuximab group. The overall side effects risk ratio suggested statistically significant difference between patients treated with cetuximab and pa- tients with no cetuximab (RR=1.11, 95% CI 1.01-1.20, P<0.05, P =47%).
CONCLUSION
The 2 year progression-free survival and overall survival were similar between cetuximab group and no cetuximab group in patients with locally advanced head and neck squamous cell cancer. Data are limited and the benefits of cetuximab on this outcome remain uncertain. Impact of grade 3-4 dysphagia was similar in both groups, however, the incidence of grade 3-4 mucositis and skin reaction were lower in patients treated with cetuximab. Existing randomized controlled trials provided a scientific evidence for the use of cetuximab in R/M HNSCC. The conclusion of the study is based on limited number of RCT, so further investigation is still needed before firm recommendations of cetuximab can be made in the treatment of HNSCC.
Antibodies, Monoclonal, Humanized
;
therapeutic use
;
Antineoplastic Agents
;
therapeutic use
;
Carcinoma, Squamous Cell
;
drug therapy
;
Cetuximab
;
Disease-Free Survival
;
Head and Neck Neoplasms
;
drug therapy
;
Humans
;
Squamous Cell Carcinoma of Head and Neck
8.Effects of dexmedetomidine on lidocaine-induced apoptosis in rat cortical neurons
Dongjian GE ; Bin QI ; Jinyu LI
Chinese Journal of Anesthesiology 2013;33(9):1079-1081
Objective To evaluate the effects of dexmedetomidine on lidocaine-induced apoptosis in rat cortical neurons.Methods The cortical neurons obtained from Sprague-Dawley fetal rats were seeded in 24 multiwell plates at a density of 1 × 105 cells/ml,and the cortical neurons of 80 wells were randomly divided into 4 groups (n =20 each):control group (group C),lidocaine group (group L),dexmedetomidine group (group D) and lidocaine + dexmedetomidine group (group L+ D).The cells were cultured routinely in group C.The cells were exposed to lidocaine with a final concentration of 1 mmol/L in group L.The cells were exposed to dexmedetomidine with a final concentration of 3 μmol/L in group D.The cells were exposed to lidocaine and dexmedetomidine with the final concentrations of 1 mmol/L and 3 μmol/L,respectively,in group L + D.After 4 h incubation,the neurons were subjected to DAPI staining for detection of apoptosis,and the apoptosis rate was calculated.Western blot analysis was used to measure the expression of phosphorylated Akt (p-Akt),Akt and caspase-3.Results Compared with group C,the apoptosis rate was significantly increased,the expression of p-Akt was down-regulated,and the expression of caspase-3 was up-regulated in L and L + D groups (P < 0.05),while no significant changes were found in the indexes mentioned above in group D (P > 0.05).Compared with group L,the apoptosis rate was significantly decreased,the expression of p-Akt was up-regulated,and the expression of caspase-3 was down-regulated in L + D group (P < 0.05).There was no significant difference in the expression of Akt between the four groups (P > 0.05).Conclusion Dexmedetomidine can reduce lidocaine-induced apoptosis in rat cortical neurons,and activation of Akt may be involved in the underlying mechanism.
9.The protective effect of dexmedetomidine preconditioning on acute lung injury in rats
Dongjian GE ; Bin QI ; Jinyu LI
Chongqing Medicine 2013;(28):3405-3407
Objective To investigate the role of Akt signaling in the protective effect of dexmedetomidine preconditioning on the lipopolysaccharide(LPS)-induced acute lung injury (ALI) in rat .Methods Twenty-two SD rats were randomly divided into 4 groups:before LPS injection group(T0 group) ,1 h after LPS injection group(T1 group) ,3 h after LPS injection group(T2 group) and 6 h after LPS injection group(T3 group) ,the expression of Akt and p-Akt in the process of LPS-induced ALI was investigated . Another 54 rats were divided into 3 groups :control group(C group) ,6 hours of ALI group(ALI group) and Dexmedetomidine+ALI group(D+ ALI group) ,the expression of p-Akt in lung tissues ,the protein concentration in bronchoalveolar lavage fluid (BALF) ,apoptotic index and the pathological changes in the lung tissues were observed .Forty rats were divided into ALI group and ALI + D group to investigate the 48 h-survival ratio .Results Compared with T0 group ,the level of p-Akt expression in T1 ,T2 , T3 groups were deceased in a time-dependent manner(P<0 .05) .Compared with ALI group ,p-Akt in D + ALI group increased significantly(P<0 .05) but was still lower than that in C group(P<0 .05);the protein concentration in BALF and the apoptotic in-dex in D + ALI groups were significantly lower than those in ALI group(P<0 .05) ,but still higher than those in C group(P<0 .05) .The 48 h survival ratio was significantly decreased in D + ALI group comparing with ALI group(P<0 .05) .Conclusion Dexmedetomidine preconditioning might display protective effect via activating p-Akt signaling pathway in LPS-induced ALI .
10.Acupuncture master Xu Yi-nian and his Practical Acupuncture in the Republic of China.
Chinese Acupuncture & Moxibustion 2014;34(9):926-928
By collecting and studying Practical Acupuncture written by XU Yi-nian, Guangdong acupuncture master in the Republic of China, and using literature methodology, the life story of XU Yi-nian is textually researched and his acupuncture characteristics is analyzed. The results indicate that XU Yi-nian emphasizes on the utility of acupuncture manipulations and acupoint selection, the application of folk experiences in moxibustion and Sha disorders. He pays attention to the co-work of acupuncture and medicine and his work collects the therapeutic experiences of different schools and deserves to be further explored and validated.
Acupuncture Therapy
;
history
;
instrumentation
;
Books
;
history
;
China
;
History, 20th Century
;
Humans
;
Moxibustion
;
history
;
methods